Latest ViiV Healthcare Stories
Unique public-private collaboration will create HIV Cure center and a new company to bring together academic and pharmaceutical research scientists CHAPEL HILL, N.C., May 10, 2015
LONDON, May 6, 2015 /PRNewswire/ -- First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced
Initial Investment to Help Research, Identify and Apply Innovative Solutions in Baltimore, Maryland and Jackson, Mississippi - Two of the Cities Hardest Hit by HIV/AIDS RESEARCH TRIANGLE
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date RESEARCH
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced
Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ --
- A handkerchief.
- In general, any miraculous portrait of Christ.